10/02/2022 - General information
The Hospital del Mar Medical Research Institute and Hospital del Mar are once again supporting the International Day of Women and Girls in Science, raising awareness of their work and trying to encourage new vocations. In the case of the IMIM, just over half of the research positions are held by women. In the 21st century, women who decide to pursue a career in the various fields of science often receive smaller research grants than their male colleagues. They hold only 12% of the positions in national science academies, while they account for a third of all researchers. Realities that make an initiative like the International Day of Women and Girls in Science and campaigns such as She Inspired Me more necessary than ever.
Més informació "Towards full and equal access to and participation in science for women and girls"
11/02/2022 - General information
The head of the Infectious Diseases Department at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group at the Hospital del Mar Medical Research Institute, was appointed to this body, which is part of the European Medicines Agency (EMA), last month. The European Medicines Agency (EMA) has selected Dr. Juan Pablo Horcajada, head of the Infectious Diseases Department at Hospital del Mar and coordinator of the Infectious Pathology and Antimicrobial Research Group at the Hospital del Mar Medical Research Institute (IMIM) as a member of its Scientific Advisory Group on Infectious Diseases. This is a body comprising experts in this field from several European countries, chosen by the agency after a selection process, following a proposal from the national medicines agencies.
31/01/2022 - General information
Glioblastoma and oral drugs for various types of cancer are among the targets of the projects for the first phase, selected from among more than a hundred proposals, due to their clinical and industrial relevance The project "PARP2: a new therapeutic target in c-myc-driven tumours", headed up by Dr. José Yélamos, coordinator of the Poly (ADP-ribose) polymerase research group at the Hospital del Mar Medical Research Institute (IMIM) and the Immunology Service at Hospital del Mar, has been selected in the first edition of the Cancer Innova initiative, a consortium comprising the Kaertor Foundation and the Spanish Association Against Cancer in collaboration with the pharmaceutical companies Janssen and Lilly, which is supported by the Galician regional government. On this occasion, 110 proposals from eight countries were submitted, of which just five were selected based on their high clinical and industrial impact.
28/01/2022 - General information
The renowned chef gave an online session in which she explained that it is possible to eat well and healthily and still enjoy food. The talk, organised by the Hospital del Mar Medical Research Institute's Neurosciences programme, is part of the cognitive and social stimulation sessions for volunteers in the PENSA project on the prevention of cognitive impairment. Can you eat healthily and still get excited about what you eat? The answer is yes. This was explained by Ada Parellada, the chef and director of Restaurant Semproniana and 2016 Creu de Sant Jordi winner, who this morning visited the facilities at the Hospital de Mar Medical Research Institute (IMIM) as a guest of the Institute's Neuroscience Programme. Her visit was part of the PENSA project, promoted by the programme, in collaboration with the Barcelonaβeta Brain Research Centre from the Pasqual Maragall Foundation.
26/01/2022 - General information
The technique achieves good results in terms of toxicity, the preservation of the physical appearance and patient ratings when used for partial breast irradiation compared to its use in combination with large doses of fractionated whole-breast irradiation. Patients with early-stage breast cancer more positively evaluate treatment with partial intraoperative radiotherapy of the breast than the approach that uses the same technique in combination with whole-breast irradiation divided into large doses. This is highlighted in a study published in the journal Clinical and Translational Oncology, led by the Radiation Oncology Service and the Functional Breast Pathology Unit at Hospital del Mar as well as researchers in the Radiation Oncology Research Group at the Hospital del Mar Medical Research Institute.
Més informació "Partial intraoperative radiotherapy in breast cancer, more highly rated by patients"
25/01/2022 - General information
A study by CiSAL and CIBERESP shows that, once they have returned to work, they work at a lower rate than those who have not suffered from the disease. Men and women who had no sick leave or who were on sick leave for other illnesses were at least 9% more likely to continue working compared to workers who took cancer-related sick leave, according to this study carried out in Catalonia and published in 'Scientific Reports'. Not being able to work when you can and want to leads to a loss of self-esteem and social relationships, which can make recovering from cancer psychologically difficult", explains Fernando G. Benavides, the coordinator of the study.
18/01/2022 - General information
The predoctoral researcher Lilian Boll from the Evolutionary Genomics Research Group of the GRIB (IMIM-UPF) has obtained one of the 65 grants of the INPhINIT PhD Program of La Caixa Foundation for her project "Identification of neo-epitopes in cancer derived from non-canonical proteins and their potential use in immunotherapy" to study neoantigens. Neoantigens are tumor-specific antigens generated by mutations in tumor cells, which are only expressed in tumor cells. "One of the approaches in immunotherapy is to block cellular checkpoints so that the immune system recognizes tumor cells by their neoantigens," explains Lilian Boll.
11/01/2022 - General information
The Government Delegation for the National Plan on Drugs has awarded the White Cross of the Order of Merit to Dr. Antònia Domingo-Salvany, who was the coordinator of the Epidemiology of Drugs of Abuse Research Group at the IMIM until 2017. This is public recognition and thanks for the work she has accomplished over a career spanning almost 30 years in the field of substance use epidemiology. Dr. Domingo has made a major contribution to our understanding of the extent and impact of drug use in the population, including aspects related to violence and illegal drug market activities, and has collaborated in the implementation of appropriate health initiatives. With her group, she has conducted studies to assess the magnitude of drug use in the population, contributing to the knowledge of its consequences, including psychiatric comorbidities, the presence of blood-borne infections, and quality of life-related health impairment. She has also been involved in studies that sought to evaluate tools for detecting substance use disorders in various settings, as well as potential associated psychiatric problems.
27/12/2021 - General information
AELIS FARMA, a biotechnology company specializing in the treatment of brain disorders, announces today that AEF0217 has been administered to the first cohort of healthy volunteers, as part of a phase 1 clinical study to assess the safety, tolerability and the pharmacokinetic characteristics of its second drug candidate. The administration of AEF0217, using a dose in the expected therapeutic range, has good tolerability and demonstrates encouraging safety and plasma exposure characteristics for further clinical development. This phase 1 program is part of the European H2020 ICOD project (Improving COgnition in Down syndrome) which is led in collaboration with Hospital del Mar Medical Research Institute (IMIM) in Barcelona, and Prof. Raphael de la Torre Fornell, coordinator of the project and the principal investigator of the study. In February 2021, the ICOD project received funding of €6m from the European Commission to finance the clinical development of AEF0217 for the treatment of cognitive deficits linked to Down syndrome.
20/12/2021 - General information
The urgent need to find treatments for a large number of degenerative diseases has led a group of experts to develop a guide designed to accelerate new drug discoveries for neurological and psychiatric diseases. Project leads are Dr. Silvia Zaragoza Domingo, consultant and founder of Neuropsynchro, Barcelona, serving as coordinator collaborating with Drs. Jordi Alonso and Montserrat Ferrer, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM) and CIBERESP, and Dr. Manuel de Gracia, Facultat de Psicologia of Universitat de Girona (UdG). This guide was presented during the 34th Congress of the European Clinical Neurosychopharmacological College (ECNP) in Lisbon on 2-5 October and has been the group's priority project since it was established in 2018.
Servei de Comunicació:
Marta Calsina Freixas(ELIMINAR)
Tel:
(+34) 93 316 06 80
Doctor Aiguader, 88
08226 Barcelona
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact